Consultation on a provisional agreement with Norgine Pty Ltd for the terms of listing of Movicol (macrogol 3350) on the Pharmaceutical Schedule

Medicines

Consultation Closed

PHARMAC and Norgine Pty Ltd have entered into a provisional agreement to list Movicol (macrogol 3350 with sodium chloride, sodium bicarbonate, and potassium chloride) in the Pharmaceutical Schedule.

It is anticipated that PHARMAC’s Board (or Acting Chief Executive under delegated authority) will consider this proposal in August 2007.

If the proposal is approved it would mean:

  • Movicol would be listed in Section B and Section H of the Pharmaceutical Schedule from 1 October 2007.
  • The price and subsidy for Movicol in Section B, and the price for Movicol in Section H of the Pharmaceutical Schedule, would be as follows from (ex-manufacturer, excluding GST):

Pharmaceutical

Form

Strength (per sachet)

Pack Size

Price / Subsidy

Macrogol 3350 with Sodium Chloride, Sodium Bicarbonate,
Potassium Chloride

Powder

Macrogol 3350: 13.125 g
Sodium chloride: 350.7 mg
Sodium bicarbonate: 178.5 mg
Potassium chloride: 46.6 mg

30 sachets

$18.14

  • All subsidised units of Movicol dispensed in the community and purchased by District Health Board Hospitals would be subject to a confidential rebate.
  • Movicol would be listed in Section B of the Pharmaceutical Schedule subject to Special Authority criteria substantially in the form set out below:

Initial application by any relevant practitioner. Approvals valid for 6 months where the patient has problematic constipation requiring intervention with a per rectal preparation despite an adequate trial of other oral pharmacotherapies, including lactulose.

Renewal from any relevant practitioner.  Approvals valid for 6 months where the patient is compliant and is continuing to gain benefit from treatment.

  • Movicol C would be listed on the Pharmaceutical Schedule subject to the volume restriction substantially in the form set out below:

No more than two x 30 sachet packs per prescription

PHARMAC welcomes feedback on this proposal. If you wish to make comments on any aspect of this proposal for the PHARMAC Board to consider when making its decision on whether to accept this proposal, please forward them to PHARMAC by 4:00 pm, 17 August 2007.  All comments submitted by this date will be considered.